Tomasz Marek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomasz Marek has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Ewa Nowakowska-Duława
Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice, Poland
13 shared publications A. Nowak
7 shared publicationsJ.-F. Rey
5 shared publications- Marek Hartleb
Medical University of Silesia, Katowice, Poland
5 shared publications R. Kaczor
5 shared publicationsAndrzej Nowak
4 shared publications
Latest Publications
- 19 March 2021
- Published by Georg Thieme Verlag KG
- Vol. 53 (S 01) , OP202
The Feasibility Study Of Polish Young Endoscopists Group For Upper Gastrointestinal Preparation Scale Validation – The Polprep Scale
Aims Mucosal cleanliness is crucial for detection of abnormalities of mucosa during endoscopic examinations. Although numerous preparation scales for colonoscopy have been worked-out, no validated scale for upper gastrointestinal tract has been developed so far. The aim of our study was to develop and validate easy to use upper gastrointestinal scale estimating quality of mucosal visibility. Methods We have developed four-point scale (0-3) assessing mucosal visibility in the esophagus, stomach and duodenum.This scale was used twice by 12 endoscopists (7 trainees and 5 consultants) to assess 18 photographs of esophagus, stomach and duodenum (second time after two weeks). Inter- and intra-observer reproducibility was calculated. Photo documentation obtained according to ESGE guidelines and endoscopy report of 443 patients who underwent complete diagnostic esophagogastroduodenoscopy (EGD) in 6 endoscopic centers were retrospectively analyzed. Photographs were assessed according to POLPREP scale by two independent clinicians. Endoscopic data: reflux esophagitis, endoscopic suspicion of esophageal metaplasia, esophageal tumors, cervical inlet patch, gastric tumors, gastric polyps and ulcers, duodenal ulcers, duodenal polyps, post-ulcer duodenal bulb deformation and duodenal tumor was recorded. Results The inter-observer reproducibility in use of POLPREP was 0.8 (0.85 for trainees and 0.79 for consultants). The Fleiss Kappa value estimating intra-observer reproducibility was 0.64 (the value was equal in whole assessed group, trainees and consultants). The inter-observer reproducibility values for esophagus, stomach and duodenum were: 0.74, 0.83 and 0.82, respectively. The difference in detection rate of endoscopic findings for inadequate preparation (points 1) and adequate preparation (points 2 and 3) among assessed segments was statistically significant (7.7 % and 19.7 % respectively; p= 0.049). The odds ratio for the detection of abnormalities was 3.2 for point 3 in comparison to point 1 (95 %CI 1.1-9; p=0.03). Conclusions The POLPREP scale might be a potential tool to inform about mucosal visibility in EGD. Citation: Romańczyk M, Ostrowski B, Kozłowska-Petriczko K et al. OP202 THE FEASIBILITY STUDY OF POLISH YOUNG ENDOSCOPISTS GROUP FOR UPPER GASTROINTESTINAL PREPARATION SCALE VALIDATION – THE POLPREP SCALE. Endoscopy 2021; 53: S83. Publication Date: 19 March 2021 (online) © 2021. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 19 March 2021
- Published by Georg Thieme Verlag KG
- Vol. 53 (S 01) , OP202
The Feasibility Study Of Polish Young Endoscopists Group For Upper Gastrointestinal Preparation Scale Validation – The Polprep Scale
Aims Mucosal cleanliness is crucial for detection of abnormalities of mucosa during endoscopic examinations. Although numerous preparation scales for colonoscopy have been worked-out, no validated scale for upper gastrointestinal tract has been developed so far. The aim of our study was to develop and validate easy to use upper gastrointestinal scale estimating quality of mucosal visibility. Methods We have developed four-point scale (0-3) assessing mucosal visibility in the esophagus, stomach and duodenum.This scale was used twice by 12 endoscopists (7 trainees and 5 consultants) to assess 18 photographs of esophagus, stomach and duodenum (second time after two weeks). Inter- and intra-observer reproducibility was calculated. Photo documentation obtained according to ESGE guidelines and endoscopy report of 443 patients who underwent complete diagnostic esophagogastroduodenoscopy (EGD) in 6 endoscopic centers were retrospectively analyzed. Photographs were assessed according to POLPREP scale by two independent clinicians. Endoscopic data: reflux esophagitis, endoscopic suspicion of esophageal metaplasia, esophageal tumors, cervical inlet patch, gastric tumors, gastric polyps and ulcers, duodenal ulcers, duodenal polyps, post-ulcer duodenal bulb deformation and duodenal tumor was recorded. Results The inter-observer reproducibility in use of POLPREP was 0.8 (0.85 for trainees and 0.79 for consultants). The Fleiss Kappa value estimating intra-observer reproducibility was 0.64 (the value was equal in whole assessed group, trainees and consultants). The inter-observer reproducibility values for esophagus, stomach and duodenum were: 0.74, 0.83 and 0.82, respectively. The difference in detection rate of endoscopic findings for inadequate preparation (points 1) and adequate preparation (points 2 and 3) among assessed segments was statistically significant (7.7 % and 19.7 % respectively; p= 0.049). The odds ratio for the detection of abnormalities was 3.2 for point 3 in comparison to point 1 (95 %CI 1.1-9; p=0.03). Conclusions The POLPREP scale might be a potential tool to inform about mucosal visibility in EGD. Citation: Romańczyk M, Ostrowski B, Kozłowska-Petriczko K et al. OP202 THE FEASIBILITY STUDY OF POLISH YOUNG ENDOSCOPISTS GROUP FOR UPPER GASTROINTESTINAL PREPARATION SCALE VALIDATION – THE POLPREP SCALE. Endoscopy 2021; 53: S83. Publication Date: 19 March 2021 (online) © 2021. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 14 (1) , 1-18
Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
These recommendations refer to the current management in pancreatic ductal adenocarcinoma (PDAC), a neoplasia characterised by an aggressive course and extremely poor prognosis. The recommendations regard diagnosis, surgical, adjuvant and palliative treatment, with consideration given to...
- 1 January 2019
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 14 (1) , 1-18
Open AccessDiagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
These recommendations refer to the current management in pancreatic ductal adenocarcinoma (PDAC), a neoplasia characterised by an aggressive course and extremely poor prognosis. The recommendations regard diagnosis, surgical, adjuvant and palliative treatment, with consideration given to...
- 2 December 2018
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 53 (12) , 1503-1508
Mucosal miR-3677 is over-expressed in cirrhotic patients with gastric antral vascular ectasia (GAVE)
Introduction: Gastric antral vascular ectasia (GAVE) is a rare vasculopathy that associates several diseases, most commonly liver cirrhosis. It usually presents as an occult gastrointestinal bleeding leading to profound iron deficiency anemia. We hypothesized that GAVE is local mucosal pathology dependent on genetic mechanisms, and the purpose of the study was to characterize miRNAs expression in gastric tissue of patients with cirrhosis and GAVE. Materials and methods: Thirteen patients with GAVE and cirrhosis and 35 healthy subjects were recruited. Microarray analysis and comparative microRNA study was done by quantitative polymerase chain reaction (qPCR). The microarray scores were grouped with use of the hierarchical clusterization analysis and miRNA target prediction was done with TargetScan 6.2 algorithm and Gene Ontology analysis (DIANA-miRPath). Results: Concentration of miR-3677 in GAVE-affected mucosa was higher by 72% in comparison with GAVE-free mucosa of patients with cirrhosis (33.7 vs. 35.6 PCR cycles; p < .001) and by 45% in comparison with normal mucosa (33.7 vs. 34.9 PCR cycles; p < .05). According to Gene Ontology analysis miR-3677 was related to angiopoietin-like protein 4 (ANGPTL4) gene. Conclusion: GAVE in liver cirrhosis is associated with increased expression of miR-3667 that may be linked with ANGPTL4 gene.
- 2 December 2018
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 53 (12) , 1503-1508
Mucosal miR-3677 is over-expressed in cirrhotic patients with gastric antral vascular ectasia (GAVE)
Introduction: Gastric antral vascular ectasia (GAVE) is a rare vasculopathy that associates several diseases, most commonly liver cirrhosis. It usually presents as an occult gastrointestinal bleeding leading to profound iron deficiency anemia. We hypothesized that GAVE is local mucosal pathology dependent on genetic mechanisms, and the purpose of the study was to characterize miRNAs expression in gastric tissue of patients with cirrhosis and GAVE. Materials and methods: Thirteen patients with GAVE and cirrhosis and 35 healthy subjects were recruited. Microarray analysis and comparative microRNA study was done by quantitative polymerase chain reaction (qPCR). The microarray scores were grouped with use of the hierarchical clusterization analysis and miRNA target prediction was done with TargetScan 6.2 algorithm and Gene Ontology analysis (DIANA-miRPath). Results: Concentration of miR-3677 in GAVE-affected mucosa was higher by 72% in comparison with GAVE-free mucosa of patients with cirrhosis (33.7 vs. 35.6 PCR cycles; p < .001) and by 45% in comparison with normal mucosa (33.7 vs. 34.9 PCR cycles; p < .05). According to Gene Ontology analysis miR-3677 was related to angiopoietin-like protein 4 (ANGPTL4) gene. Conclusion: GAVE in liver cirrhosis is associated with increased expression of miR-3667 that may be linked with ANGPTL4 gene.
- Open Access
- 1 January 2018
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 14 (4) , 439-443
Case reports of patients with significantly elevated CA 19-9 levels without confirmed malignancy
The CA 19-9 antigen is a marker whose concentration is elevated usually in the presence of gastrointestinal cancer. CA 19-9 is considered to be characteristic for pancreatic and biliary cancer; however, an elevated level of this marker may also indicate a cancer with a different point of origin such as the colon or the stomach. CA 19-9 has limited application in diagnosis; however, the observation of its level makes it possible to monitor treatment progress and can help in the detection of cancer spread. CA 19-9 is a glycoprotein with a molecular mass of 210 kD, produced not only by cancer cells, but also by gastrointestinal and liver cells during foetal development, by salivary glands, mature pancreatic and biliary cells as well as the bronchi. This study presents the cases of patients who were diagnosed with significantly elevated CA 19-9 levels and in whom cancer was excluded in the course of further clinical follow-up. The authors indicate that a very high concentration of CA 19-9 can have a different cause than cancer: in the cases described in the present study it was usually cholestasis caused by benign biliary diseases that led to the elevation of this marker.
- 1 January 2018
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 14 (4) , 439-443
Open AccessCase reports of patients with significantly elevated CA 19-9 levels without confirmed malignancy
The CA 19-9 antigen is a marker whose concentration is elevated usually in the presence of gastrointestinal cancer. CA 19-9 is considered to be characteristic for pancreatic and biliary cancer; however, an elevated level of this marker may also indicate a cancer with a different point of origin such as the colon or the stomach. CA 19-9 has limited application in diagnosis; however, the observation of its level makes it possible to monitor treatment progress and can help in the detection of cancer spread. CA 19-9 is a glycoprotein with a molecular mass of 210 kD, produced not only by cancer cells, but also by gastrointestinal and liver cells during foetal development, by salivary glands, mature pancreatic and biliary cells as well as the bronchi. This study presents the cases of patients who were diagnosed with significantly elevated CA 19-9 levels and in whom cancer was excluded in the course of further clinical follow-up. The authors indicate that a very high concentration of CA 19-9 can have a different cause than cancer: in the cases described in the present study it was usually cholestasis caused by benign biliary diseases that led to the elevation of this marker.
- 1 October 2016
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 28 (10) , 1223-1228
Comparison of patency and cost-effectiveness of self-expandable metal and plastic stents used for malignant biliary strictures
Most patients with malignant biliary obstruction are suited only for palliation by endoscopic drainage with plastic stents (PS) or self-expandable metal stents (SEMS). To compare the clinical outcome and costs of biliary stenting with SEMS and PS in patients with malignant biliary strictures. A total of 114 patients with malignant jaundice who underwent 376 endoscopic retrograde biliary drainage (ERBD) were studied. ERBD with the placement of PS was performed in 80 patients, with one-step SEMS in 20 patients and two-step SEMS in 14 patients. Significantly fewer ERBD interventions were performed in patients with one-step SEMS than PS or the two-step SEMS technique (2.0±1.12 vs. 3.1±1.7 or 5.7±2.1, respectively, P<0.0001). The median hospitalization duration per procedure was similar for the three groups of patients. The patients' survival time was the longest in the two-step SEMS group in comparison with the one-step SEMS and PS groups (596±270 vs. 276±141 or 208±219 days, P<0.001). Overall median time to recurrent biliary obstruction was 89.3±159 days for PS and 120.6±101 days for SEMS (P=0.01). The total cost of hospitalization with ERBD was higher for two-step SEMS than for one-step SEMS or PS (1448±312, 1152±135 and 977±156&OV0556;, P<0.0001). However, the estimated annual cost of medical care for one-step SEMS was higher than that for the two-step SEMS or PS groups (4618, 4079, and 3995&OV0556;, respectively). Biliary decompression by SEMS is associated with longer patency and reduced number of auxiliary procedures; however, repeated PS insertions still remain the most cost-effective strategy.
- 1 October 2016
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 28 (10) , 1223-1228
Comparison of patency and cost-effectiveness of self-expandable metal and plastic stents used for malignant biliary strictures
Most patients with malignant biliary obstruction are suited only for palliation by endoscopic drainage with plastic stents (PS) or self-expandable metal stents (SEMS). To compare the clinical outcome and costs of biliary stenting with SEMS and PS in patients with malignant biliary strictures. A total of 114 patients with malignant jaundice who underwent 376 endoscopic retrograde biliary drainage (ERBD) were studied. ERBD with the placement of PS was performed in 80 patients, with one-step SEMS in 20 patients and two-step SEMS in 14 patients. Significantly fewer ERBD interventions were performed in patients with one-step SEMS than PS or the two-step SEMS technique (2.0±1.12 vs. 3.1±1.7 or 5.7±2.1, respectively, P<0.0001). The median hospitalization duration per procedure was similar for the three groups of patients. The patients' survival time was the longest in the two-step SEMS group in comparison with the one-step SEMS and PS groups (596±270 vs. 276±141 or 208±219 days, P<0.001). Overall median time to recurrent biliary obstruction was 89.3±159 days for PS and 120.6±101 days for SEMS (P=0.01). The total cost of hospitalization with ERBD was higher for two-step SEMS than for one-step SEMS or PS (1448±312, 1152±135 and 977±156&OV0556;, P<0.0001). However, the estimated annual cost of medical care for one-step SEMS was higher than that for the two-step SEMS or PS groups (4618, 4079, and 3995&OV0556;, respectively). Biliary decompression by SEMS is associated with longer patency and reduced number of auxiliary procedures; however, repeated PS insertions still remain the most cost-effective strategy.
- Open Access
- 6 January 2016
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 24 (8) , 1228-1231
The HLA-DQβ1 insertion is a strong achalasia risk factor and displays a geospatial north–south gradient among Europeans
Idiopathic achalasia is a severe motility disorder of the esophagus and is characterized by a failure of the lower esophageal sphincter to relax due to a loss of neurons in the myenteric plexus. Most recently, we identified an eight-amino-acid insertion in the cytoplasmic tail of HLA-DQβ1 as strong achalasia risk factor in a sample set from Central Europe, Italy and Spain. Here, we tested whether the HLA-DQβ1 insertion also confers achalasia risk in the Polish and Swedish population. We could replicate the initial findings and the insertion shows strong achalasia association in both samples (Poland P=1.84 × 10−04, Sweden P=7.44 × 10−05). Combining all five European data sets – Central Europe, Italy, Spain, Poland and Sweden – the insertion is achalasia associated with Pcombined=1.67 × 10−35. In addition, we observe that the frequency of the insertion shows a geospatial north–south gradient. The insertion is less common in northern (around 6–7% in patients and 2% in controls from Sweden and Poland) compared with southern Europeans (~16% in patients and 8% in controls from Italy) and shows a stronger attributable risk in the southern European population. Our study provides evidence that the prevalence of achalasia may differ between populations.
- 6 January 2016
- Published by Springer Nature in European Journal of Human Genetics
- Vol. 24 (8) , 1228-1231
Open AccessThe HLA-DQβ1 insertion is a strong achalasia risk factor and displays a geospatial north–south gradient among Europeans
Idiopathic achalasia is a severe motility disorder of the esophagus and is characterized by a failure of the lower esophageal sphincter to relax due to a loss of neurons in the myenteric plexus. Most recently, we identified an eight-amino-acid insertion in the cytoplasmic tail of HLA-DQβ1 as strong achalasia risk factor in a sample set from Central Europe, Italy and Spain. Here, we tested whether the HLA-DQβ1 insertion also confers achalasia risk in the Polish and Swedish population. We could replicate the initial findings and the insertion shows strong achalasia association in both samples (Poland P=1.84 × 10−04, Sweden P=7.44 × 10−05). Combining all five European data sets – Central Europe, Italy, Spain, Poland and Sweden – the insertion is achalasia associated with Pcombined=1.67 × 10−35. In addition, we observe that the frequency of the insertion shows a geospatial north–south gradient. The insertion is less common in northern (around 6–7% in patients and 2% in controls from Sweden and Poland) compared with southern Europeans (~16% in patients and 8% in controls from Italy) and shows a stronger attributable risk in the southern European population. Our study provides evidence that the prevalence of achalasia may differ between populations.
- Top Cited Papers
- 22 August 2014
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 46 (09) , 799-815
Prophylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Updated June 2014
This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the prophylaxis of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis. Main recommendations 1 ESGE recommends routine rectal administration of 100 mg of diclofenac or indomethacin immediately before or after ERCP in all patients without contraindication. In addition to this, in the case of high risk for post-ERCP pancreatitis (PEP), the placement of a 5-Fr prophylactic pancreatic stent should be strongly considered. Sublingually administered glyceryl trinitrate or 250 µg somatostatin given in bolus injection might be considered as an option in high risk cases if nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated and if prophylactic pancreatic stenting is not possible or successful. 2 ESGE recommends keeping the number of cannulation attempts as low as possible. 3 ESGE suggests restricting the use of a pancreatic guidewire as a backup technique for biliary cannulation to cases with repeated inadvertent cannulation of the pancreatic duct; if this method is used, deep biliary cannulation should be attempted using a guidewire rather than the contrast-assisted method and a prophylactic pancreatic stent should be placed. 4 ESGE suggests that needle-knife fistulotomy should be the preferred precut technique in patients with a bile duct dilated down to the papilla. Conventional precut and transpancreatic sphincterotomy present similar success and complication rates; if conventional precut is selected and pancreatic cannulation is easily obtained, ESGE suggests attempting to place a small-diameter (3-Fr or 5-Fr) pancreatic stent to guide the cut and leaving the pancreatic stent in place at the end of ERCP for a minimum of 12 – 24 hours. 4 ESGE does not recommend endoscopic papillary balloon dilation as an alternative to sphincterotomy in routine ERCP, but it may be advantageous in selected patients; if this technique is used, the duration of dilation should be longer than 1 minute.
- 22 August 2014
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 46 (09) , 799-815
Top Cited PapersProphylaxis of post-ERCP pancreatitis: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Updated June 2014
This Guideline is an official statement of the European Society of Gastrointestinal Endoscopy (ESGE). It addresses the prophylaxis of post-endoscopic retrograde cholangiopancreatography (post-ERCP) pancreatitis. Main recommendations 1 ESGE recommends routine rectal administration of 100 mg of diclofenac or indomethacin immediately before or after ERCP in all patients without contraindication. In addition to this, in the case of high risk for post-ERCP pancreatitis (PEP), the placement of a 5-Fr prophylactic pancreatic stent should be strongly considered. Sublingually administered glyceryl trinitrate or 250 µg somatostatin given in bolus injection might be considered as an option in high risk cases if nonsteroidal anti-inflammatory drugs (NSAIDs) are contraindicated and if prophylactic pancreatic stenting is not possible or successful. 2 ESGE recommends keeping the number of cannulation attempts as low as possible. 3 ESGE suggests restricting the use of a pancreatic guidewire as a backup technique for biliary cannulation to cases with repeated inadvertent cannulation of the pancreatic duct; if this method is used, deep biliary cannulation should be attempted using a guidewire rather than the contrast-assisted method and a prophylactic pancreatic stent should be placed. 4 ESGE suggests that needle-knife fistulotomy should be the preferred precut technique in patients with a bile duct dilated down to the papilla. Conventional precut and transpancreatic sphincterotomy present similar success and complication rates; if conventional precut is selected and pancreatic cannulation is easily obtained, ESGE suggests attempting to place a small-diameter (3-Fr or 5-Fr) pancreatic stent to guide the cut and leaving the pancreatic stent in place at the end of ERCP for a minimum of 12 – 24 hours. 4 ESGE does not recommend endoscopic papillary balloon dilation as an alternative to sphincterotomy in routine ERCP, but it may be advantageous in selected patients; if this technique is used, the duration of dilation should be longer than 1 minute.
- 1 January 2014
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 2, 63-68
Therapeutic and prophylactic management of bleeding from oesophageal and gastric varices – recommendations of the Working Group of the National Consultant for Gastroenterology
Gastroesophageal varices are one of the most serious consequences of portal hypertension. One-third of patients with varices will develop variceal haemorrhage. Despite significant improvements in the outcomes of treatment, mortality due to bleeding from gastro-oesophageal varices still remains...
- 1 January 2014
- Published by Termedia Sp. z.o.o. in Gastroenterology Review
- Vol. 2, 63-68
Therapeutic and prophylactic management of bleeding from oesophageal and gastric varices – recommendations of the Working Group of the National Consultant for Gastroenterology
Gastroesophageal varices are one of the most serious consequences of portal hypertension. One-third of patients with varices will develop variceal haemorrhage. Despite significant improvements in the outcomes of treatment, mortality due to bleeding from gastro-oesophageal varices still remains...
- 1 February 2013
- Vol. 64 (1) , 109-14
Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Aim of the study was to investigate the value of serum and bile neutrophil gelatinase-associated lipocalin (NGAL) for distinguishing malignant strictures caused by cholangiocarcinoma (CCA) or pancreatic cancer from benign biliary strictures. The study was performed prospectively on patients admitted for endoscopic or radiologic biliary decompression. Forty patients with dilated biliary ducts, including 16 cases of CCA, 6 cases of pancreatic cancer, and 18 cases of benign biliary stricture were enrolled. Their sera and bile were collected to measure NGAL. Routine biochemistry including measurement of serum levels of carbohydrate antigens (CA) 19-9 and carcinoembryonic antigen (CEA) was also performed. The serum CA19-9, serum CEA, and bile NGAL levels were significantly increased in patients with malignant strictures as compared with patients with benign biliary diseases. Serum NGAL had no significant value for discriminating between malignant and benign biliary strictures. Bile NGAL levels had a receiver characteristic area under the curve of 0.74, sensitivity 77.3, and specificity 72.2% for discriminating between pancreatobiliary cancer and benign biliary diseases. Bile NGAL and serum CA19-9 were independent parameters and their combined use improved diagnostic accuracy (sensitivity 91%, negative predictive value 85.7%). We conclude that measurement of biliary, but not serum NGAL, may differentiate malignant pancreatobiliary from benign biliary strictures, serving as a complementary biomarker for serum CA19-9.
- 1 February 2013
- Vol. 64 (1) , 109-14
Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Aim of the study was to investigate the value of serum and bile neutrophil gelatinase-associated lipocalin (NGAL) for distinguishing malignant strictures caused by cholangiocarcinoma (CCA) or pancreatic cancer from benign biliary strictures. The study was performed prospectively on patients admitted for endoscopic or radiologic biliary decompression. Forty patients with dilated biliary ducts, including 16 cases of CCA, 6 cases of pancreatic cancer, and 18 cases of benign biliary stricture were enrolled. Their sera and bile were collected to measure NGAL. Routine biochemistry including measurement of serum levels of carbohydrate antigens (CA) 19-9 and carcinoembryonic antigen (CEA) was also performed. The serum CA19-9, serum CEA, and bile NGAL levels were significantly increased in patients with malignant strictures as compared with patients with benign biliary diseases. Serum NGAL had no significant value for discriminating between malignant and benign biliary strictures. Bile NGAL levels had a receiver characteristic area under the curve of 0.74, sensitivity 77.3, and specificity 72.2% for discriminating between pancreatobiliary cancer and benign biliary diseases. Bile NGAL and serum CA19-9 were independent parameters and their combined use improved diagnostic accuracy (sensitivity 91%, negative predictive value 85.7%). We conclude that measurement of biliary, but not serum NGAL, may differentiate malignant pancreatobiliary from benign biliary strictures, serving as a complementary biomarker for serum CA19-9.
- 28 September 2009
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 41 (S 02) , E256
Fatal case of biliary cast syndrome in nontransplant patient
A 69-year-old male, with no history of liver disease, was admitted after several days of low-grade fever, weakness, and jaundice, preceded by dyspepsia and diarrhea that occurred during recent holidays in North Africa. Laboratory tests revealed anemia (hemoglobin 7.7 g/dL), inflammation (C-reactive protein 148 mg/L, white blood cells 16.6 g/L), and liver injury (alkaline phosphatase [ALP] 426 U/L, gamma glutamyl transpeptidase [GGT] 160 U/L, alanine aminotransferase [ALT] 90 U/L, aspartate aminotransferase [AST] 114 U/L, bilirubin rapidly rising to 22 mg/dL). All possible etiologies of liver injury were excluded. Abdominal ultrasound and computed tomography revealed an enlarged liver with multiple focal lesions requiring differentiation between abscesses, metastases, or hamartomas ([ Fig. 1 ] and [ 2 ]). Endoscopic retrograde cholangiography showed irregular filling defects in extra- and intrahepatic bile ducts, with cystic dilations of intrahepatic ducts, suggestive of microabscesses ([ Fig. 3 ]). Outflow of pus with sludge was observed after sphincterotomy. Escherichia coli was cultured from bile. Repeated attempts to remove the casts with a Dormia basket were unsuccessful. The patient’s condition deteriorated despite intensive care, and he died of progressive liver failure. On autopsy, the biliary tree, including small branches, was filled with cast replicating the ductal system ([ Fig. 4 ]). Liver histopathology showed diffuse bile stasis in hepatocytes and portal fibrosis with mild inflammation. Fig. 1 Ultrasound of the liver. Fig. 2 Computed tomography. Fig. 3 Endoscopic retrograde cholangiography. Irregular filling defects (biliary casts) visible in both exta- and intrahepatic bile ducts (white arrows). Black arrows show cystic dilation of intrahepatic bile ducts presumed to be microabscesses. Fig. 4 Autopsy. Arrows show biliary casts protruding from bile ducts on the cross-section of the liver. Biliary cast syndrome is defined as the presence of casts (caused by retained lithogenic material) within the intra- and/or extrahepatic bile ducts, causing obstruction and cholangitis, eventually complicated by multiple strictures, ductal dilation, and/or liver microabscesses. Biliary cast syndrome used to be a common fatal complication in the early years of liver transplantation, and was related to poor graft preparation [ 1 ] [ 2 ]. When possible, biliary cast syndrome is treated endoscopically or surgically, including by liver transplantation [ 3 ] [ 4 ] [ 5 ]. There are only a few reports of biliary cast syndrome in nontransplant patients [ 3 ] [ 4 ] [ 5 ]. In the presented case the infection responsible for travellers’ diarrhea and presumably cholangitis was the most probable triggering event in the development of casts. The involvement of small intrahepatic branches made endoscopic treatment ineffective and was responsible for liver failure. Endoscopy_UCTN_Code_CCL_1AZ_2AJ
- 28 September 2009
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 41 (S 02) , E256
Fatal case of biliary cast syndrome in nontransplant patient
A 69-year-old male, with no history of liver disease, was admitted after several days of low-grade fever, weakness, and jaundice, preceded by dyspepsia and diarrhea that occurred during recent holidays in North Africa. Laboratory tests revealed anemia (hemoglobin 7.7 g/dL), inflammation (C-reactive protein 148 mg/L, white blood cells 16.6 g/L), and liver injury (alkaline phosphatase [ALP] 426 U/L, gamma glutamyl transpeptidase [GGT] 160 U/L, alanine aminotransferase [ALT] 90 U/L, aspartate aminotransferase [AST] 114 U/L, bilirubin rapidly rising to 22 mg/dL). All possible etiologies of liver injury were excluded. Abdominal ultrasound and computed tomography revealed an enlarged liver with multiple focal lesions requiring differentiation between abscesses, metastases, or hamartomas ([ Fig. 1 ] and [ 2 ]). Endoscopic retrograde cholangiography showed irregular filling defects in extra- and intrahepatic bile ducts, with cystic dilations of intrahepatic ducts, suggestive of microabscesses ([ Fig. 3 ]). Outflow of pus with sludge was observed after sphincterotomy. Escherichia coli was cultured from bile. Repeated attempts to remove the casts with a Dormia basket were unsuccessful. The patient’s condition deteriorated despite intensive care, and he died of progressive liver failure. On autopsy, the biliary tree, including small branches, was filled with cast replicating the ductal system ([ Fig. 4 ]). Liver histopathology showed diffuse bile stasis in hepatocytes and portal fibrosis with mild inflammation. Fig. 1 Ultrasound of the liver. Fig. 2 Computed tomography. Fig. 3 Endoscopic retrograde cholangiography. Irregular filling defects (biliary casts) visible in both exta- and intrahepatic bile ducts (white arrows). Black arrows show cystic dilation of intrahepatic bile ducts presumed to be microabscesses. Fig. 4 Autopsy. Arrows show biliary casts protruding from bile ducts on the cross-section of the liver. Biliary cast syndrome is defined as the presence of casts (caused by retained lithogenic material) within the intra- and/or extrahepatic bile ducts, causing obstruction and cholangitis, eventually complicated by multiple strictures, ductal dilation, and/or liver microabscesses. Biliary cast syndrome used to be a common fatal complication in the early years of liver transplantation, and was related to poor graft preparation [ 1 ] [ 2 ]. When possible, biliary cast syndrome is treated endoscopically or surgically, including by liver transplantation [ 3 ] [ 4 ] [ 5 ]. There are only a few reports of biliary cast syndrome in nontransplant patients [ 3 ] [ 4 ] [ 5 ]. In the presented case the infection responsible for travellers’ diarrhea and presumably cholangitis was the most probable triggering event in the development of casts. The involvement of small intrahepatic branches made endoscopic treatment ineffective and was responsible for liver failure. Endoscopy_UCTN_Code_CCL_1AZ_2AJ